Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

Ji Quan Wang, Mingzhang Gao, Kathy Miller, George W. Sledge, Qi-Huang Zheng

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/μmol specific activity at end of bombardment (EOB).

Original languageEnglish
Pages (from-to)4102-4106
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume16
Issue number15
DOIs
StatePublished - Aug 1 2006

Fingerprint

Positron emission tomography
Epidermal Growth Factor Receptor
Positron-Emission Tomography
Protein-Tyrosine Kinases
Imaging techniques
Neoplasms
Signal transduction
Signal Transduction
Repair
Cells
Apoptosis
gefitinib

Keywords

  • Cancer imaging
  • Carbon-11
  • Epidermal growth factor receptor tyrosine kinase (EGFR-TK)
  • Iressa
  • Positron emission tomography (PET)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. / Wang, Ji Quan; Gao, Mingzhang; Miller, Kathy; Sledge, George W.; Zheng, Qi-Huang.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 16, No. 15, 01.08.2006, p. 4102-4106.

Research output: Contribution to journalArticle

@article{6111a7b4f6104174875a31f6d0662307,
title = "Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase",
abstract = "Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40{\%} radiochemical yield with 4.0-6.0 Ci/μmol specific activity at end of bombardment (EOB).",
keywords = "Cancer imaging, Carbon-11, Epidermal growth factor receptor tyrosine kinase (EGFR-TK), Iressa, Positron emission tomography (PET)",
author = "Wang, {Ji Quan} and Mingzhang Gao and Kathy Miller and Sledge, {George W.} and Qi-Huang Zheng",
year = "2006",
month = "8",
day = "1",
doi = "10.1016/j.bmcl.2006.04.080",
language = "English",
volume = "16",
pages = "4102--4106",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

AU - Wang, Ji Quan

AU - Gao, Mingzhang

AU - Miller, Kathy

AU - Sledge, George W.

AU - Zheng, Qi-Huang

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/μmol specific activity at end of bombardment (EOB).

AB - Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/μmol specific activity at end of bombardment (EOB).

KW - Cancer imaging

KW - Carbon-11

KW - Epidermal growth factor receptor tyrosine kinase (EGFR-TK)

KW - Iressa

KW - Positron emission tomography (PET)

UR - http://www.scopus.com/inward/record.url?scp=33748423744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748423744&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2006.04.080

DO - 10.1016/j.bmcl.2006.04.080

M3 - Article

VL - 16

SP - 4102

EP - 4106

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 15

ER -